Omega 3 improves memory in patients of schizophrenia with Metabolic syndrome

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2020-07-01 11:18 GMT | Update On 2020-07-02 05:13 GMT

China: Omega-3 fatty acids have beneficial effects on cognitive function in patients with schizophrenia and metabolic syndrome (MetS), a recent study in the Brain, Behavior, and Immunity has found.

Previous studies have shown metabolic abnormalities to be associated with reduced levels of brain-derived neurotrophic factor (BDNF) and deteriorated cognitive performance in schizophrenia patients. Inflammation may play a key role in this process and omega-3 fatty acids have been documented to ameliorate inflammation. Therefore, Wei Tang, The Affiliated Kangning Hospital of Wenzhou Medical University, Zhejiang, China, and colleagues hypothesized that omega-3 fatty acids may be of value in enhancing BDNF levels and improving cognitive function in patients with schizophrenia with metabolic syndrome.

The researchers recruited 80 patients with both schizophrenia and MetS who received long-term olanzapine monotherapy. The plasma levels of C-reactive protein (CRP), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) were measured through the enzyme-linked immunosorbent assay.

The patients were randomly assigned to the OMG-3 group (n = 40) or the placebo group (n = 40). Of the 80 patients who consented to the study, 72 completed this 12-week RCT. The primary outcome was the changes from baseline to 12 weeks in clinical characteristics and the levels of BDNF, CRP, IL-6, and TNF-α.

Key findings of the study include:

There was a significant correlation between omega-3 fatty acid treatment and enhanced delayed memory factor in the RBANS assessment when the patients completed this study.
Along with cognitive improvement, omega-3 fatty acids enhanced BDNF and reduced CRP, IL-6 and TNF-α levels after 12 weeks of treatment.
The changes in BDNF levels are negatively correlated with the changes in TNF-α levels but not with the changes in CRP and IL-6 levels.

"Our findings provide suggestive evidence that omega-3 fatty acids have beneficial effects on cognitive function in patients with MetS, which is paralleled by enhanced BDNF levels," concluded the authors.

The study, "Omega-3 fatty acids ameliorate cognitive dysfunction in schizophrenia patients with metabolic syndrome," is published in the journal Brain, Behavior, and Immunity.

DOI: https://doi.org/10.1016/j.bbi.2020.04.034

Article Source : Brain, Behavior, and Immunity

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Omega 3 improves memory in patients of schizophrenia with Metabolic syndrome

Similar News

GLP-1 Receptor Agonists Improve Metabolic Outcomes in Schizophrenia Patients on Antipsychotics: JAMA

Long-Standing Diabetes Significantly Increases Dementia Risk in Heart Attack Survivors, Study Finds

Some mental conditions raise heart disease risk, mortality rate by nearly 100%, reveals study

Moderate-to-regular daily sleep patterns are associated with enhanced cognitive function: Study

People with schizophrenia have higher risk of COPD, suggests study

Seltorexant effective in initiating sleep in individuals with insomnia: JAMA

WHO Releases Landmark Reports on Global Mental Health and Suicide Estimates

Sleep problems in early teens associated with future self-harm: Study